Diazyme DZ-Lite SARS-CoV-2 IgM CLIA Kit
Independent Performance Validation Study
The Diazyme DZ-Lite SARS-CoV-2 IgM CLIA kit is an Emergency Use Authorization (EUA) test authorized by the U.S. FDA for use by authorized laboratories. The test is for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum and plasma (potassium EDTA, disodium EDTA and lithium heparin) to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
The DZ-Lite SARS-CoV-2 IgM CLIA kit runs on the fully automated DZ-Lite 3000 Plus Chemiluminescence Analyzer
The assay features:
100 tests/kit and is used in conjunction with the fully automated DZ-Lite 3000 Plus Chemiluminescence Analyzer